



Transgender Research: Five Things Every Parent and Policy-Maker Should Know[©]

September 2022

READING ONLY THE BLUE TEXT PROVIDES AN EXECUTIVE SUMMARY OF THIS DOCUMENT

The past 10 years have seen an exponential rise in the occurrence of gender confusion or gender dysphoria (also called transgender or gender non-conforming)* among young people worldwide, especially among teenage girls. The distress of these young people is real, and the causes of this unprecedented trend are unclear, raising difficult questions about compassionate, ethical, and effective ways to respond. Experts disagree, with some recommending watchful waiting plus counseling and some asserting that cross-sex medical procedures are necessary in order to prevent suicide. The U.S. federal policy of the current administration, which endorses “early gender affirming care” for “children and adolescents” (HHS, 2022), is considered controversial by many. And the dramatic rise in use of cross-sex hormones and surgery for young people has been the focus of heated debate, causing uncertainty in patients, parents, physicians, and policy-makers as to what is best. Below is a summary of the latest research on five key questions about these issues, shared in the hope of helping gender-confused young people receive the best care.

1. What does research show about the benefits and harms of cross-sex medical treatment for minors?

Scientific evidence has not shown that cross-sex medical treatments are beneficial to children or adolescents. The research making these claims is not scientifically reliable. In fact, there is evidence of harmful impact. Consequently, a growing number of scientific agencies do not recommend such treatments. Instead, they recommend counseling and watchful waiting for gender-confused youth.

Summary of Evidence

Many scientific agencies—both U.S. and international—do not recommend medical “transition” for youth because the research claiming to show positive effects from cross-sex hormones or surgery is methodologically flawed and not scientifically reliable. The limitations of these studies include lack of control groups, small sample sizes, recruitment bias, nongeneralizable study populations, short follow-up times, and high numbers lost to follow-up. However, studies finding negative outcomes from medical transition tend to be of adequate scientific quality. In other words, reliable studies have shown harmful effects. “Watchful waiting,” is the option recommended by many scientific agencies. It means deferring transgender interventions for gender-confused children or youth for an extended time during which counseling can occur and a natural desistance or persistence process can play out.

Highlights from Published Research (studies are listed by first author and year):

Sweden National Board of Health & Welfare (NBHW), 2022

- “For adolescents...the NBHW deems that the risks of puberty suppressing treatment...and gender-affirming hormonal treatment currently outweigh the possible benefits...based on...continued lack of reliable scientific evidence concerning the efficacy and the safety of both treatments.”

British National Health Service - The Cass Review, February 2022

- “At this stage the Review is not able to provide advice on the use of hormone treatments due to gaps in the evidence base...Evidence on the appropriate management of children and young people with gender incongruence and dysphoria is inconclusive both nationally and internationally.”

British National Institute for Health and Care Excellence (NICE) Evidence review, 2020a

- The studies on the impact of puberty blockers “are of very low certainty [i.e., quality] using the G.R.A.D.E. rating system. They suggest little change...from baseline to follow-up...As the studies all lack appropriate control [groups], any positive changes could be a regression to [the] mean.”
- The G.R.A.D.E. (Grading of Recommendations, Assessment, Development and Evaluations, or GRADE) rating system is the most widely adopted tool for grading the quality of [research] evidence.

The British Medical Journal (BMJ) Evidence Review, 2019 (Henagan, C. & Jefferson, T.)

One of the foremost scientific publications in the world concluded:

- “Puberty blockers are being used in the context of profound scientific ignorance...treatments for under 18 gender dysphoric children and adolescents remain largely experimental. There are a large number of unanswered questions that include the age at start, reversibility; adverse events, long term effects on mental health, quality of life, bone mineral density, osteoporosis in later life and cognition...The current evidence base does not support informed decision making and safe practice in children.”

Finland Board for Selection of Choices for Health Care (PALKO / COHERE Finland), 2020

“*Medical Treatment Methods for Dysphoria Related to Gender Variance in Minors:*”

- “The first-line treatment for gender dysphoria is psychosocial support and, as necessary, psychotherapy and treatment of possible comorbid psychiatric disorders.”
- “The reliability of the existing studies with no control groups is highly uncertain, and because of this uncertainty, no decisions should be made that can permanently alter a still-maturing minor’s mental and physical development ... In light of available evidence, gender reassignment of minors is an experimental practice...no irreversible treatment should be initiated.”
- “Surgical treatments are not part of the treatment methods for dysphoria caused by gender-related conflicts in minors.” Hormonal interventions may be considered on a case-by-case basis after extensive evaluation.

U.S. Food & Drug Administration (FDA), 2022

- The FDA added a warning to the labeling for puberty blocking hormones (GnRH agonists): “to monitor patients taking GnRH agonists for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred or loss of vision, diplopia, pain behind the eye or pain with eye movement, tinnitus, dizziness and nausea.”
- “These hormones [puberty blockers] have FDA approval only for the treatment of precocious puberty [not gender dysphoria] in pediatric patients.” They are not approved for...halting normally timed puberty. (AbbVie, 2018).

U.S. Medicare National Coverage Analysis (NCA) – Decision Memo, 2016

- “Based on an extensive assessment of the clinical evidence...there is not enough high-quality evidence to determine whether gender reassignment surgery improves health outcomes...”

Hruz, 2020

“Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria.”

- “It is important to recognize the low quality of scientific evidence used in generating treatment recommendations ... [For example], nearly all of the recommendations made by the Endocrine Society were based upon “low” or “very low” quality evidence [according to the GRADE rating system]... The limitations of the published studies in...transgender medicine are many. They include a general lack of randomized controlled trial design, small sample sizes, high potential for recruitment bias, ...nongeneralizable population groups, relatively short follow-up, [and] high numbers of patients lost to follow-up... The only data that reached the level of “moderate” quality were related to adverse [i.e., harmful] medical outcomes...risks include low bone density, altered adult height, and impaired spatial memory (de Vries et al. 2011; Hough et al. 2017).”

deVries, 2014

For example, this flawed study is widely cited as evidence that cross-sex hormones are beneficial to youth, yet:

- It had no control group, used a non-representative sample, and had an inadequate sample size—only 32 people for mental health outcomes, with key results based on subgroups as small as 12.
- Thus, the flawed results for 12 patients have been widely used to justify giving cross-sex hormones to children.

Levine, 2022

- “When evidence is assessed to be “very low certainty” [by GRADE], there is a high likelihood that the patients will not experience the [claimed] effects of the proposed interventions (Balslem et al., 2011).”
- “In the context of providing puberty blockers and cross-sex hormones, the [GRADE] designation of ‘very low certainty’ signals that the body of evidence asserting the benefits of these interventions is highly unreliable.”
- “In contrast, several negative effects are quite certain. For example, puberty blockade followed by cross-sex hormones leads to infertility and sterility (Laidlaw, Van Meter, Hruz, Van Mol, & Malone, 2019). Surgeries to remove breasts or sex organs are irreversible. Other health risks includ[e] risks to bone and cardiovascular health.”

Alzahrani, 2019; Nota, 2019; Getahun, 2018

- At least three studies have found significantly elevated rates of acute cardiovascular events (such as heart attacks and strokes) in transgender adults who have received cross-sex hormone treatment.

Turner, 2022

An investigation of Britain’s Gender Identity Development Service (GIDS) for *The Times Magazine* found:

- “A barely pubescent child prescribed [puberty] blockers who goes on to take cross-sex hormones—as almost every patient does—will be infertile and unable to orgasm.”
- Transgender lobby groups influenced GIDS in favor of medical transition of children, despite scientific evidence.
- Britain’s National Health Service is closing the GIDS clinic due to concerns about patient safety (Glebova, 2022).

Cantor, 2020

- “Although almost all clinics and professional associations in the world use what’s called the watchful waiting approach to helping transgender and gender diverse (GD) children, the AAP [American Academy of Pediatrics] statement rejected that consensus, endorsing only gender affirmation. That is, where the consensus is to delay any transitions [until] after the onset of puberty, AAP instead rejected waiting before transition... As I read the works on which they based their policy, I was...alarmed: These documents simply did not say what AAP claimed they did. In fact, the references that AAP cited as the basis of their policy instead outright contradicted that policy, repeatedly endorsing watchful waiting.”

The Society for Evidence-Based Gender Medicine, 2022

- A review of the cited scientific support for the U.S. Department of Health & Human Services recent policy statement that “For transgender and nonbinary children and adolescents, early gender affirming care is crucial to overall health and well-being” (HHS Office of Population Affairs, 2022) found misstatements of study findings, use of one flawed study as evidence for major claims, misrepresentation of treatment “reversibility,” lack of evidence for the claims made, a failure to discuss the well-documented risks, and no presentation of alternatives.

2. What does research on medical gender transition tell us about preventing suicide in trans youth?

Research does not show that medical gender transition is necessary to prevent suicide. In fact, there is evidence that medical transition procedures may increase suicide risk in gender-confused teens.

Summary of Evidence

The “transition or suicide” claim—that parents must choose between a “live trans son or a dead daughter” (or vice-versa)—is not supported by scientific evidence. Widely cited studies claiming that suicidality in gender-confused youth is reduced by cross-sex hormonal and surgical interventions have been found to have significant methodological flaws and therefore should not be relied on. Scientifically sound studies have found either no reduction or an increase in transgender suicidality after youth have received cross-sex medical procedures.

Highlights from Published Research:

Dhejne, 2011

A Swedish study recognized as a landmark 30-year longitudinal study of life after transgender surgery found that...

- Ten years after sex reassignment surgery, the transgender patients were 19 times more likely to die from suicide than the typical Swedish population, after accounting for differences in individual mental illness before surgery.
- Those transitioning “male-to-female are at higher risk for suicide attempts after sex reassignment.”
- The study authors concluded: “...surgery and hormonal therapy...is apparently not sufficient to remedy the high rates of [mental illness] and mortality found among transsexual persons... Our findings suggest that sex reassignment, although alleviating gender dysphoria, may not suffice as treatment for transsexualism...”
- A U.S. Medicare National Coverage Analysis (NCA) Decision Memo (2016), which reviewed this Dhejne study, stated: “we cannot exclude therapeutic interventions [i.e., transgender surgery] *as a cause* of the observed excess [mental illness] and mortality” (p. 62, emphasis added).

Heylens, 2014

- Although the study reported a reduction in patients’ psychological distress, there was no reduction in suicide attempts at any step in the process of cross-sex medical intervention.

Bauer, 2015

- Although there was a decrease in “suicidal thoughts” after cross-sex hormonal intervention, among those who did have suicidal thoughts, being in the process of cross-sex medical treatment was associated with a three-fold increase in actual suicide attempts.

Adams, 2017

A meta-analysis of 42 studies of suicidality in transgender adults reported...

- Suicidal thoughts appeared to increase after medical transition and suicide attempts did not appear to decrease.

Branstrom, 2020b

A 10-year study on the impact of cross-sex hormones and/or surgery on patients’ mental health, found...

- “...the results demonstrated no [positive effects] of surgery in relation to subsequent mood or anxiety disorder-related health care visits or prescriptions or hospitalizations following suicide attempts.”

Wiepjes, 2020

- “An important finding was that the incidence for observed suicide deaths was almost equally distributed over the different stages of treatment” (i.e., the suicide rate was roughly the same before and after cross-sex surgery).

Turban, 2020

A weak study widely cited as showing that puberty blockers reduce suicidality, actually obscured contradictory findings:

- The study employed the inferior correlational research design which is not able to test causality.
- The study Abstract (or summary) reported that puberty blockers had reduced Suicidal Thoughts in adolescents, but the author failed to include in the Abstract that there was no reduction in the more serious measures of suicidality: Suicide Attempts, Lifetime Suicide Attempts, and Suicide Attempts Resulting in Hospitalization—all key findings.
- The study results suggest that recent suicide attempts may have increased after puberty blockers, although not significant due to small numbers. And 75% of those who received puberty blockers still had suicidal thoughts.

Carmichael, 2021

- A recent study, patterned after an early study in the Netherlands that said puberty blockers improved mental health in transgender youth (deVries, 2011), found puberty blockers had no positive effect on mental health or suicidality.

Turban, 2022

A recent study cited as evidence that cross-sex hormones during adolescence reduce suicidality in adults, obscured contradictory findings and seemed to downplay evidence suggesting increased suicidality for 16-17-year-old patients:

- The study used the weak correlational research design, lacked adequate control for some confounding factors, such as pre-existing mental health, and combined the effects of two very different hormones (testosterone and estrogen).
- The study Abstract reported a reduction in Suicidal Thoughts for those starting cross-sex hormones by age 17 as evidence of “favorable outcomes” from this treatment. But there was no reduction in the more serious measures of suicidality—Suicidal Thoughts with Plan, Suicide Attempt, or Suicide Attempt requiring Hospitalization—related to the use of cross-sex hormones at any age. As in his previous study (Turban, 2020), the author failed to include these contradictory and more important findings in the Abstract, where key results/non-results should be reported.
- 16- and 17-year-olds who received hormones were more than twice as likely to report a “past-year suicide attempt requiring inpatient hospitalization” (aOR=2.2, $p<.01$). But by setting the cut-off for statistical significance much higher than is standard in empirical research (i.e., at $p<.001$ instead of $p<.05$ —a debatable Bonferroni correction) the study avoided reporting this as an increase in suicidality related to hormone therapy in adolescence.

Biggs, 2022a

A second analysis of the same data used in Turban, 2022 (above entry), found...

- Use of cross-sex hormones significantly increased suicidality (nearly two-fold) for biological males receiving estrogen—increases in Suicidal Thoughts with Plan, Suicide Attempt, and Suicide Attempt Requiring Hospitalization—when the effects were analyzed separately for biological males compared to females.
- Receiving puberty blockers in adolescence did not reduce any measure of suicidality.

Tordoff, 2022; Reddit 2022

This flawed study is purported to show that cross-sex hormones reduced depression and suicidality rates in 57 adolescents:

- However, the study reported no significant declines in these rates from baseline to the 12-month follow-up; they remained high, at 56% depressed and 37% with suicidal thoughts, 12 months after the start of hormonal treatment.
- The hormonal “reductions” were claimed because the rates did not *increase* as they did for the group not receiving hormones, whose rates increased greatly by the 12-month follow-up. But unlike the hormone group, this group had 82% drop out of the study, reducing it to only 7 youth and invalidating its use as a legitimate comparison group.
- These data, in the study Supplement, do not show that cross-sex hormones improved mental health in trans youth.

Biggs, 2022b

Longitudinal analysis of patient records from the world’s largest clinic for transgender youth:

- There was no difference in the suicide rate for those who had not yet received treatment and those who had received treatment (puberty blockers and/or cross-sex hormones).
- “It is irresponsible to exaggerate the prevalence of suicide... Data from the world’s largest clinic for transgender youth, accumulated over an 11-year period, [found that] ... The proportion of individual patients who died by suicide was 0.03% [or 3 out of 10,000], which is orders of magnitude smaller than the proportion of transgender adolescents who report attempting suicide when surveyed.”
- The finding that [actual] deaths were so rare is helpful information for transgender youth and their families.

Levine, 2022

- “The “transition or suicide” narrative falsely implies that transition will prevent suicides... [Yet,] neither hormones nor surgeries have been shown to reduce suicidality in the long-term... [Thus,] the “transition or die” narrative, whereby parents are told that their only choice is between a “live trans daughter or a dead son” (or vice-versa), is both factually inaccurate and ethically wrong.”

3. Is gender dysphoria in children a permanent condition, and one that requires medical treatment?

Research shows gender dysphoria in children usually goes away on its own by young adulthood, if “transition” is not encouraged. This avoids the harmful effects of cross-sex medical interventions.

Summary of Evidence

There is strong evidence showing that the vast majority (averaging about 85%) of children who experience gender dysphoria will resolve their gender identity confusion and accept their biological sex by the time they reach young adulthood, that is, if they are not subjected to “social transition” or cross-sex medical intervention. But for those who are the subject of early transition efforts, the large majority will most likely persist in a “trans” identity. (“Social transition” refers to cross-sex dressing and social reinforcement of a transgender identity for children by adults.)

Highlights from Published Research:

Steensma, 2015

- “In long-term follow-up [into young adulthood], the childhood sample showed 66.7% desistence.” That is, by young adulthood, two-thirds of those with childhood gender dysphoria did not identify as transgender. (As quoted in Cantor, 2020.)

Ristori & Steensma, 2016

- A review of 10 studies measuring the persistence of childhood gender dysphoria found that, by the follow-up time in adolescence or young adulthood, 2% to 39% of cases had persisted in gender dysphoria or transgender identity, resulting in an average of 85% who identified with their biological sex at that point.

Zucker, 2018

- Results of four studies: “Among children meeting the diagnostic criteria for “Gender Dysphoria” ...67% were no longer gender-dysphoric as adults; the rate of natural resolution for gender dysphoria was 93% for children whose gender dysphoria was significant but [did not reach a medical] diagnosis” (as quoted by Levine, 2022).

Singh, 2021

- 88% of boys with childhood gender dysphoria did not identify as transgender by young adulthood.

Steensma, 2013

- Young children who experience early social “transitioning” (i.e., cross-sex dressing and identification and “affirmation” of a transgender role by adults) are more likely to persist in a transgender identity.

de Vries et al. 2011

- None of the youth who received puberty blocker hormones desisted in their cross-sex identification; all went on to take cross-sex gender-transition hormones (whose negative side-effects include infertility, see Cheng, et al., 2019).

4. Can young people be influenced to identify as transgender, or is it all biologically determined?

Scientific evidence indicates that the causes of gender dysphoria are complex. Social and cultural factors can have a significant influence on whether a young person will identify as transgender.

Summary of Evidence

Recent unprecedented increases in transgender identity worldwide suggest that non-biological influences are a major factor. Studies show gender identity development is a complex process with bio-psycho-social components. This means children and young people are susceptible to social, educational, and cultural influences.

Highlights from Published Research:

Heylans, 2012

A systematic review of research on identical twins and gender dysphoria...

- Concluded that the 39% concordance rate for transgender identity in identical twins (i.e., where both were transgender) was “consistent with a genetic influence...although shared and nonshared environmental factors cannot be ruled out... [Gender identity development] is a complex process of biopsychosocial components.”
- While this suggests “a role for genetic factors in the development of [gender dysphoria],” it also indicates a significant role played by social and environmental factors for many individuals.
- The study found the influence of social factors was higher for biological females than males.

Jones, 2021

- A recent U.S. Gallup Poll found that the percent of Generation Z (born 1997 – 2002) who identify as transgender has increased by 900% over the percent of Generation X (born 1965 – 1980), who say they are transgender.

The Economist, 2020; Turner, 2022

- In Great Britain, between 2010 and 2020, the number of teenage girls referred for gender dysphoria (GD) to the largest pediatric gender clinic in the world, increased by about 5000%, while the rates for girls under age 12 saw only small increases. Rates for teenage boys also increased dramatically, although much less than for girls, with similarly small increases for boys under 12. In Sweden, GD in teen girls has risen 1500% in a similar time span.
- This pattern suggests that the exponential increase in GD for teen girls (which did not occur for preteens) may be due to social influence, i.e., transgender identity promotion, rather than merely an increase in public acceptance.

Zucker, 2019; Littman, 2018 & 2019

- There has been a recent dramatic reversal in the male-to-female sex ratio of transgender youth, with biological females now far out-numbering males (the previous consistent ratio of about 2:1 has now changed to a ratio ranging from 1:2 to 1:7), coupled with a corresponding recent dramatic “increase in the number of adolescents referred to specialized gender identity clinics/programs [which] has become an international phenomenon, observed all across North America, Europe, Scandinavia, and elsewhere” (Zucker, 2019).
- These changes are considered by some experts to be an important new clinical phenomenon that needs to be studied and better understood, especially the role of social influences (Zucker 2019, Littman, 2018/9).

Downey, 2022; Mason, 2022

- A popular researcher advocating for the use of puberty blockers in children—who has been funded by an agency that receives financial support from the makers of puberty blockers—claims to have shown that social influence is not a cause of the recent worldwide explosion in rates of gender dysphoria. However, his research has been criticized for its use of an invalid survey measure and for using only U.S. data, as well as for a conflict of interest.

5. What does research tell us about teaching sex education and gender ideology to young children?

There is no scientific evidence showing that young children benefit from being taught in school about sexuality, transgender identity, or homosexuality, or that such teaching reduces child sex abuse.

Summary of Evidence

Studies to date have not produced scientific evidence to back up the claim that teaching sex education to young children in early elementary school, including content about transgender ideology and homosexuality, is beneficial to them or reduces rates of child sex abuse. There are no sound studies on these outcomes. And research has not shown reliable evidence that sex education classes which teach these topics to older youth produce any long-term benefits.

Highlights from Published Research

Goldfarb & Lieberman, 2021; critique of Goldfarb & Lieberman by Erickson & Weed, 2022

Contrary to its claims, a recent review of research on school-based sex education in the U.S. and internationally...

- Showed no credible scientific evidence that sexuality education is beneficial to children in early elementary school or that it reduces child sex abuse. No scientifically sound studies were cited on this question.
- Presented no scientifically credible research demonstrating that teaching young children in school settings about transgender ideology or homosexuality was beneficial to them or had any other positive impact. No scientifically sound studies were cited on this question.
- Studies cited as showing benefits from teaching transgenderism and homosexuality in sex education classes for older grades were not scientifically capable of measuring this impact and also showed conflicting results.

SUMMARY of FINDINGS

1) Research evidence does not support medical intervention for gender-confused minors. 2) Medical transition procedures have not been shown to reduce youth suicides. 3) Childhood gender dysphoria usually dissipates on its own by adulthood. 4) The dramatic increase in gender dysphoria in the past decade is likely being driven by social factors. 5) Sex education for early elementary school children, including content about transgender ideology, has not been shown by scientific research to be beneficial.

* GLOSSARY of TERMS

For the purposes of this paper, we use the following definitions:

Gender Dysphoria: A diagnostic term for a person experiencing profound discomfort with their biological/natal sex.

Gender Confusion: A nonclinical term that refers to a person's feeling of not identifying with his or her biological sex.

Transgender: This refers to a person whose declared gender identity does not match that person's biological sex at birth.

Gender Non-Conforming: This term refers to a person whose behavior or appearance does not conform to prevailing cultural and social expectations about what is appropriate for their biological sex at birth.

REFERENCES

- AbbVie. 2018. Lupron Depot (Leuprolide acetate) Product Monograph. Chicago: AbbVie Corporation.
- Adams, N., M. Hitomi, and C. Moody. 2017. "Varied Reports of Adult Transgender Suicidality: Synthesizing and Describing the Peer-Reviewed and Gray Literature." *Transgender Health* 2:60–75.
- Alzahrani, T., Nguyen, T., Ryan, A., Dwairy, A., McCaffrey, J., Yunus, R., Forgiione, J., Krepp, J., Nagy, C., Mazhari, R., & Reiner, J. (2019). Cardiovascular disease risk factors and myocardial infarction in the transgender population. *Circulation: Cardiovascular Quality and Outcomes*, 12(4). doi:10.1161/CIRCOUTCOMES.119.005597
- Bailey, JM, Dunne, MP, Martin, MG. (2000). Genetic and environmental influences on sexual orientation and its correlates, in an Australian twin sample. *J Pers Soc Psychol*, 78: 424-536.
- Balslem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011). GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology*, 64(4), 401–406. doi:10.1016/j.jclinepi.2010.07.015
- Bauer GR, Scheim AI, Pyne J, Travers R, Hammond R. (2015). Intervenable factors associated with suicide risk in transgender persons: a respondent driven sampling study in Ontario, Canada. *BMC Public Health*, 15:525.
- Biggs M. (2022a). "Comment on Turban et al. 2022: Estrogen Is Associated with Greater Suicidality Among Transgender [Fe]Males, and Puberty Suppression Is Not Associated with Better Mental Health Outcomes for Either Sex," figshare, journal contribution, 2022, <https://doi.org/10.6084/m9.figshare.19018868.v1>
- Biggs M. (2022b). Suicide by clinic-referred transgender adolescents in the United Kingdom. *Archives of Sexual Behavior*. <https://doi.org/10.1007/s10508-022-02287-7>
- Branstrom, R., & Pachankis, J. E. (2020b). Correction to Branstrom and Pachankis. (2020). *American Journal of Psychiatry*, 177(8), 734–734. doi:10.1176/appi.ajp.2020.1778correction
- Burke, S. M., P. T. Cohen-Kettenis, D. J. Veltman, D. T. Klink, and J. Bakker. 2014. Hypothalamic Response to the Chemo-Signal Androstadienone in Gender Dysphoric Children and Adolescents. *Front Endocrinol (Lausanne)* 5:60. doi: 10.3389/fendo.2014.00060.
- Cantor, J. M. (2020). Transgender and gender diverse children and adolescents: Fact-checking of AAP Policy. *Journal of Sex & Marital Therapy*, 46(4), 307–313. doi:10.1080/0092623X.2019.1698481
- Carmichael P, Butler G, Masic U, Cole TJ, De Stavola BL, Davidson S, et al. (2021) Short term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. *PLoS ONE* 16(2): e0243894
- Cass Review. (2022). Independent review of gender identity services for children and young people: Interim report. February 2022. "This Review was commissioned by the National Health Service (NHS) in England to make recommendations on how to improve services provided by the NHS to children and young people who are questioning their gender identity or experiencing gender incongruence and ensure that the best model for safe and effective services is commissioned." Available at: <https://cass.independent-review.uk/publications/interim-report/>
- Cheng PJ, Pastuszak AW, Myers JB, Goodwin IA, Hotaling JM. (2019). Fertility concerns of the transgender patient. *Transl Androl Urol*;8(3):209-218.
- Delemarre-van de Waal, H.A. and Cohen-Kettenis, P.T. (2006) Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects, *European Journal of Endocrinology*,155:S131–S137
- de Vries, A. L., T. D. Steensma, T. A. Doreleijers, and P. T. Cohen-Kettenis. 2011. "Puberty Suppression in Adolescents with Gender Identity Disorder: A Prospective Follow-Up Study." *Journal of Sexual Medicine* 8:2276–83. doi: 10.1111/j.1743-6109.2010.01943.x.
- Dhejne C, Lichtenstein P, Boman M, Johansson ALV, Langstrom N, et al. (2011) Long-Term Follow-Up of Transsexual Persons Undergoing Sex Reassignment Surgery: Cohort Study in Sweden. *PLoS ONE* 6(2): e16885.
- Downey C. (2022). 'Advocate Rather Than a Scientist': The Compromised Research of Child Gender-Transition Doctor Jack Turban. *National Review Online*, August 16, 2022. Available at: https://www.nationalreview.com/news/advocate-rather-than-a-scientist-the-compromised-research-of-child-gender-transition-doctor-jack-turban/?utm_source=onesignal&utm_medium=push&utm_campaign=article
- Drummond, K. D., S. J. Bradley, M. Peterson-Badali, and K. J. Zucker. 2008. "A Follow-Up Study of Girls with Gender Identity Disorder." *Developmental Psychology* 44:34–45. doi: 10.1037/0012-1649.44.1.34.
- Eriksen IH and Weed SE. (2022). "Three Decades of Research:" A New Sex Ed Agenda Wrapped in the Veneer of Science. Salt Lake City: *The Institute for Research & Evaluation*. Available at: https://institute-research.com/pdf/Rebuttal_to_Goldfarb_and_Lieberman_2021_%28IRE%209-26-22%29.pdf

- Finland Board for Selection of Choices for Health Care (PALKO / COHERE Finland). (2020). Medical Treatment Methods for Dysphoria Related to Gender Variance In Minors. Official English Translation, May 18, 2022.
- Getahun, D., Nash, R., Flanders, W. D., Baird, T. C., Becerra-Culqui, T. A., Cromwell, L., Hunkeler, E., Lash, T. L., Millman, A., Quinn, V. P., Robinson, B., Roblin, D., Silverberg, M. J., Safer, J., Slovis, J., Tangpricha, V., & Goodman, M. (2018). Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons. *Annals of Internal Medicine*, 169(4), 205–213.
- Glebova, D. (2022). English Gender-Identity Center to Close after Report Finds It Not ‘Safe.’ *National Review Online*. Available at: <https://www.nationalreview.com/news/english-gender-identity-center-to-close-after-report-finds-it-not-safe/>
- Goldfarb E, Lieberman L. (2021). Three Decades of Research: The Case for Comprehensive Sex Education. *J Adolesc Health*, 68(1):13-27. doi: 10.1016/j.jadohealth.2020.07.036
- GRADE (Grading of Recommendations, Assessment, Development and Evaluations). See: <https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/>
- Henagan, C. & Jefferson, T. (2019). Gender-affirming hormone in children and adolescents. *British Medical Journal (BMJ) Evidence Review*. Available at: <https://blogs.bmj.com/bmjebmspotlight/2019/02/25/gender-affirming-hormone-in-children-and-adolescents-evidence-review/>
- Heylens, G., G. De Cuypere, K. J. Zucker, C. Schelfaut, E. Elaut, H. Vanden Bossche, E. De Baere, et al. (2012). Gender Identity Disorder in Twins: A Review of the Case Report Literature. *Journal of Sexual Medicine* 9:751–57.
- Heylens G, Verroken C, De Cock S, T'Sjoen G, De Cuypere G. (2014). Effects of different steps in gender reassignment therapy on psychopathology: A prospective study of persons with a gender identity disorder. *J Sex Med*; 11: 119-26.
- HHS Office of Population Affairs. (2022). Gender-Affirming Care and Young People. <https://opa.hhs.gov/sites/default/files/2022-03/gender-affirming-care-young-people-march-2022.pdf>
- Hough, D., M. Bellingham, I. R. H. Haraldsen, M. McLaughlin, M. Rennie, J. E. Robinson, A. K. Solbakk, and N. P. Evans. 2017. “Spatial Memory Is Impaired by Peripubertal GnRH Agonist Treatment and Testosterone Replacement in Sheep.” *Psychoneuroendocrinology* 75:173–82. doi: 10.1016/j.psyneuen.2016.10.016.
- Hruz, P.W. (2020). Deficiencies in Scientific Evidence for Medical Management of Gender Dysphoria. *The Linacre Quarterly*, 87(1) 34-42. DOI: 10.1177/0024363919873762
- Ismail, Fatima Yousif, Ali Fatemi, and Michael V. Johnston. (2017). “Cerebral Plasticity: Windows of Opportunity in the Developing Brain.” *European Journal of Paediatric Neurology* 21:23–48. doi: 10.1016/j.ejpn.2016.07.007.
- Jones, JM. (2021). LGBT Identification Rises to 5.6% in Latest U.S. Estimate. *Gallup Poll Social Series*. February 24, 2021. Available at: <https://news.gallup.com/poll/329708/lgbt-identification-rises-latest-estimate.aspx>
- Laidlaw, M. K., Van Meter, Q. L., Hruz, P. W., Van Mol, A., & Malone, W. J. (2019). Letter to the Editor: “Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline.” *The Journal of Clinical Endocrinology & Metabolism*, 104(3), 686–687. doi:10.1210/jc.2018-01925
- Levine SB, Abbruzzese E, Mason JW. (2022): Reconsidering Informed Consent for Trans-Identified Children, Adolescents, and Young Adults, *Journal of Sex & Marital Therapy*, DOI: 10.1080/0092623X.2022.204622
- Littman L. (2018). Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. *PLoS ONE*. 13(8): e0202330. <https://doi.org/10.1371/journal.pone.0202330> PMID: 30114286
- Littman L (2019) Correction: Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. *PLoS ONE* 14(3): e0214157. <https://doi.org/10.1371/journal.pone.0214157>
- Luders, E., F. J. Sanchez, C. Gaser, A. W. Toga, K. L. Narr, L. S. Hamilton, and E. Vilain. (2009). “Regional Gray Matter Variation in Male-to-Female Transsexualism.” *Neuroimage* 46:904–7. doi: 10.1016/j.neuroimage.2009.03.048.
- Mason J. and Sapir L. (2022). The American Academy of Pediatrics’ Dubious Transgender Science. *The Wall Street Journal*, August 17, 2022. Available at: <https://www.wsj.com/articles/the-american-academy-of-pediatrics-dubious-transgender-science-jack-turban-research-social-contagion-gender-dysphoria-puberty-blockers-uk-11660732791>
- National Institute for Health and Care Excellence (NICE). (2022a). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. Available at: <https://arms.nice.org.uk/resources/hub/1070905/attachment>
- Nota, N. M., Wiepjes, C. M., de Blok, C. J. M., Gooren, L. J. G., Kreukels, B. P. C., & den Heijer, M. (2019). Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy: Results From a Large Cohort Study. *Circulation*, 139(11), 1461–1462. <https://doi.org/10.1161/CIRCULATIONAHA.118.038584>
- Reddit. (2022). “Transgender and nonbinary youth who received gender affirming medical care experienced greatly reduced rates of suicidality and depression over the course of 12 months.” This archived post, deleted in March, 2022, shows the claims initially being made about the Tordoff, et al., 2022, study. Available at: https://www.reddit.com/r/science/comments/t5kaiy/transgender_and_nonbinary_youth_who_received/
- Ristori J and Steensma TD. (2016). Gender dysphoria in childhood. *International Review of Psychiatry* 28:13-20. DOI: <https://doi.org/10.3109/09540261.2015.1115754>
- Schagen SEE, Wouters FM, Cohen-Kettenis PT, Gooren LJ, Hannema SE. (2020). Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones. *The Journal of Clinical Endocrinology & Metabolism*, Volume 105: e4252–e4263
- Singh, D., Bradley, S. J., & Zucker, K. J. (2021). A follow-up study of boys with gender identity disorder. *Frontiers in Psychiatry*, 12. doi:10.3389/fpsy.2021.632784

- Society for Evidence-Based Gender Medicine. (2021). *New Systematic Reviews of Puberty Blockers and Cross-Sex Hormones Published by NICE: Weighing potential benefits against profound long-term uncertainties*. Available at: https://segm.org/NICE_gender_medicine_systematic_review_finds_poor_quality_evidence
- Society for Evidence-Based Gender Medicine. (2022). Early Social Gender Transition in Children is Associated with High Rates of Transgender Identity in Early Adolescence. May 6, 2022. Available at: <https://segm.org/early-social-gender-transition-persistence>
- Society for Evidence-Based Gender Medicine. (2022). Fact-checking the HHS. See: <https://segm.org/fact-checking-gender-affirming-care-and-young-people-HHS>
- Steensma, T. D., & Cohen-Kettenis, P. T. (2015). More than two developmental pathways in children with gender dysphoria? *Journal of the American Academy of Child and Adolescent Psychiatry*, 52, 147–148. doi:10.1016/j.jaac.2014.10.016
- Steensma, T.D., McGuire, J.K., Kreukels, B.P., Beekman, A.J., & Cohen-Kettenis, P.T. (2013). Factors associated with desistance and persistence of childhood gender dysphoria: a quantitative follow-up study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 52, 582–590.
- Swedish National Board of Health & Welfare. (2022). *Care of Children and Adolescents with Gender Dysphoria: Summary*.
- The Economist Group Limited. (2020). An English ruling on transgender teens could have global repercussions. *The Economist*, International, December 12, 2020. Available at: <https://www.economist.com/international/2020/12/12/an-english-ruling-on-transgender-teens-could-have-global-repercussions>
- Tordoff, D.M., Wanta, J.W., Collin, A., Stepney, C., Inwards-Breland, D.J., and Ahrens, K. (2022). Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. *Pediatrics. JAMA Network Open*. 2022;5(2):e220978. doi:10.1001/jamanetworkopen.2022.0978
- Turban JL, King D, Carswell JM, Keuroghlian AS. (2020). “Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation,” *Pediatrics*, Vol. 145, No. 2, p. e20191725,
- Turban JL, King D, Kobe J, Reisner SL, Keuroghlian, (2022) “Access to Gender-Affirming Hormones During Adolescence and Mental Health Outcomes Among Transgender Adults,” *PLOS ONE*, Vol. 17, No. 1 (January 12, 2022), p. e0261039, <https://doi.org/10.1371/journal.pone.0261039>
- Turner, J. (2022). Special Report: What went wrong at the Tavistock clinic for transgender teens? *The Times Magazine*. June 17, 2022. Available at: <https://segm.org/GIDS-puberty-blockers-minors-the-times-special-report>
- U.S. Food & Drug Administration. (2022). *Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists*. Available at: https://aap2.silverchair-cdn.com/aap2/content_public/autogen-pdf/cms/20636/20636.pdf?Expires=2147483647&Signature=bhuLtZ12pTNS27GJq54IBzMVmynjPxTww6iMXeF9P4qUBbCfFnXEUEmNp1l2rHmXvh7VbZiTdsBd uxGL5q4ZvLPm-Fr7VOVtxM-n9hKHXTurpexaHK5dcE2YWyfo4-ALsTD3GMP7d2oLgMr0vFgjPhXId6DPFJLVwncClprhKlv8zWjTZLcQYtbOEy4kTOOKRsvM-S~Sn1yd7X~nT295Lnr4yO~txrKkSLY2uZlhitrc3jnLv0ruS1gMZ0XIFYKRSDfVnN3mL68psGgN9LLN2SP9p3lagUAz4Zcj00FPTmbnCxm2nxpbsfXypUGinj7 qkWuHQA7ajVmu5redYA__&Key-Pair-Id=APKAIESG5CRDK6RD3PGA
- U.S. Medicare National Coverage Analysis (NCA) Decision Memo (2016). *Gender dysphoria and gender reassignment surgery* (CAG-00446N). Centers for Medicare & Medicaid Services. Available at: <https://www.cms.gov/medicare-coverage-database/view/ncaal-decision-memo.aspx?proposed=N&NCAId=282&bc=ACAAAAAAQAAA&>
- Wiepjes, C. M., den Heijer, M., Bremmer, M. A., Nota, N. M., Blok, C. J. M., Coumou, B. J. G., & Steensma, T. D. (2020). Trends in suicide death risk in transgender people: Results from the Amsterdam Cohort of Gender Dysphoria Study (1972–2017). *Acta Psychiatrica Scandinavica*, 141(6), 486–491. doi:10.1111/acps.13164
- Zucker, K. J. (2018). The myth of persistence: Response to “A critical commentary on follow-up studies and ‘desistance’ theories about transgender and gender non-conforming children” by Temple Newhook et al. (2018). *International Journal of Transgenderism*, 19(2), 231–245. doi:10.1080/15532739.2018.1468293
- Zucker KJ. (2019). Adolescents with Gender Dysphoria: Reflections on Some Contemporary Clinical and Research Issues. *Archives of Sexual Behavior* 48:1983–1992. Available at: www.segm.org or https://link.springer.com/epdf/10.1007/s10508-019-01518-8?sharing_token=lbyqVzajww_5oCp2gORwKfe4RwlQNchNByi7wbcMAY6LN5LnWfAZ0Tvv7RsVNs8G4Hfdu_I29pZ5Oyo0lZT_TGhTswOdNyZebFztiQIyv4jzVsT_HYaBCYqpf-0VT5V5URUjxJEMdZPUO18mhGz9WBtEmM9gWkQxxcO4E_xl%3D

© 2022 The Institute for Research and Evaluation (IRE)

IRE is a nonprofit research agency that has been evaluating prevention programs for more than 30 years, specializing in sex education in schools—involving more than 100 evaluation studies and 900,000 teens, including studies in 30 U.S. states (many federally-funded) and three international countries. IRE has been an invited consultant on sex education effectiveness at the U.S. House of Representatives and Senate, The White House, and state legislatures. IRE research has been presented at the National Academies of Sciences (2019), the United Nations Civil Societies Conference (2019), and the U.S. Department of Health and Human Services (2020), and published in peer-reviewed journals, including *The American Journal of Preventive Medicine*, *The American Journal of Health Behavior*, and *Issues in Law and Medicine*.

Contact: Dr. Stan Weed at weedstan@aol.com

This document is available at: https://institute-research.com/pdf/Transgender_Research--5_Questions_for_Parents_%26_Policymakers_%28IRE%209-26-22%29.pdf